News

Merck spends $10 billion for Verona, gaining access to its COPD medication
The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.
NJBIZ19h
Merck to acquire Verona Pharma in $10B COPD drug deal
Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.
Barchart on MSN21h
What You Need To Know Ahead of Merck's Earnings Release
Valued at a market cap of $204.3 billion, Merck & Co., Inc. (MRK) is a global healthcare company with a diverse portfolio ...